Daewoong Pharma
KRX:069620
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
American Express Co
NYSE:AXP
|
Financial Services
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Target Corp
NYSE:TGT
|
Retail
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
100 600
161 100
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Estee Lauder Companies Inc
NYSE:EL
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Church & Dwight Co Inc
NYSE:CHD
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
American Express Co
NYSE:AXP
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Target Corp
NYSE:TGT
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
Mueller Industries Inc
NYSE:MLI
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Daewoong Pharma
Daewoong Pharma
Income from Continuing Operations
Daewoong Pharma
Income from Continuing Operations Peer Comparison
000100
326030
128940
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Daewoong Pharma
KRX:069620
|
Income from Continuing Operations
₩84.1B
|
CAGR 3-Years
88%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
4%
|
|
|
Yuhan Corp
KRX:000100
|
Income from Continuing Operations
₩145.9B
|
CAGR 3-Years
9%
|
CAGR 5-Years
28%
|
CAGR 10-Years
5%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Income from Continuing Operations
-₩35.4B
|
CAGR 3-Years
48%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Income from Continuing Operations
₩207.2B
|
CAGR 3-Years
87%
|
CAGR 5-Years
35%
|
CAGR 10-Years
15%
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Income from Continuing Operations
₩723.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-46%
|
CAGR 10-Years
-24%
|
|
C
|
Celltrion Pharm Inc
KOSDAQ:068760
|
Income from Continuing Operations
₩11.5B
|
CAGR 3-Years
-31%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
10%
|
See Also
What is Daewoong Pharma's Income from Continuing Operations?
Income from Continuing Operations
84.1B
KRW
Based on the financial report for Jun 30, 2024, Daewoong Pharma's Income from Continuing Operations amounts to 84.1B KRW.
What is Daewoong Pharma's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
4%
Over the last year, the Income from Continuing Operations growth was 61%. The average annual Income from Continuing Operations growth rates for Daewoong Pharma have been 88% over the past three years , and 4% over the past ten years .
You don't have any saved screeners yet
